

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/168295 A1

(51) International Patent Classification:

A61K 9/14 (2006.01) A61P 35/00 (2006.01)
A61K 31/18 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/063520

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

01 March 2023 (01.03.2023)

(25) Filing Language:

English

Published:

- with international search report (Art. 21(3))

(26) Publication Language:

English

(30) Priority Data:

63/268,723 01 March 2022 (01.03.2022) US

(71) Applicant: TVARDI THERAPEUTICS, INC. [US/US];
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land,
Texas 77478 (US).

(72) Inventors: ALIBHAI, Imran; 3 Sugar Creek Center
Boulevard, Suite 525, Sugar Land, Texas 77478 (US). DE
ACHAVAL, Sofia; 3 Sugar Creek Center Boulevard, Suite
525, Sugar Land, Texas 77478 (US). CARICOFÉ, Ralph;
4242 Six Forks Road, Suite 1550, Raleigh, North Carolina
27609 (US). WHITESELL, JR., L. Graham; 4242 Six
Forks Road, Suite 1550, Raleigh, North Carolina 27609
(US). SMART, Ian; 4242 Six Forks Road, Suite 1550,
Raleigh, North Carolina 27609 (US).

(74) Agent: DUSABAN GONZALES, Stephanie S. et al.;
100 Northern Avenue, IP DOCKETING DEPT./7TH FL,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF

(57) Abstract: Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or inflammatory disease/disorder.

WO 2023/168295 A1